The manufacture of drugs, drug products and combination products is one of the most closely regulated activities in the industry. The core of Good Manufacturing Practice is defined and determined by a variety of guidelines and regulations issued and updated regularly by national and international authorities. These have direct implications for the development, manufacturing, and reliable distribution of pharmaceutical products in regular times and even more so during a pandemic.
This and more will be the focus of the 2021 PDA Quality and Regulations Conference, set to take place on May 18-19!
The conference will take place as a Virtual Event once again this year! The online platform will offer multiple options for interactions and exchange. Receive direct feedback on your questions from distiguished experts in live Q&A sessions!
By joining this two-day event, attendees will ensure to receive the most current and thorough information on recent and most important changes in the regulatory landscape.
In the era of breakthrough medicinal therapies and technologies, accelerated R & D, Lifecycle and Change Management, Knowledge and Risk Management become pivotal milestones to ensure the manufacture and availability of these drugs.
Dive into the new decade with PDA by exploring digital solutions in Quality and don’t miss out on learnings on Control & Risk Strategies and the latest trends!
We look forward to seeing you join us online!
Vinny Browning III, Amgen
Karin Baer, Neuroderm
SCIENTIFIC PROGRAM PLANNING COMMITTEE
Vinny Browning III, Amgen - Chair
Karin Baer, Neuroderm - Chair
Graham Cook, Pfizer
Patrick Costello, Abbvie
Travis Frick, GSK
Peter Reichert, Zelect
Eva Urban, CSL Behring
Ruth Miller, PDA
Falk Klar, PDA Europe
Sylvia Becker, PDA Europe, Senior Manager Programs & Events